Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"AlzeCure Pharma AB","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Pharma to Present Late Breaking Abstract at the AAT-AD\/PD Conference (Advances in Alzheimer's and Parkinson's Therapies)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AlzeCure Pharma AB"},{"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Pharma Today Presented Key Preclinical Data on its Novel Cognitive Enhancer at the AAT-AD\/PD Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AlzeCure Pharma AB"},{"company":"CombiGene","sponsor":"Cobra Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cobra Biologics Completes Production of Master Cell Banks for CombiGene\u2019s Epilepsy Gene Therapy Drug Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"CombiGene"},{"company":"Alzinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzinova AB Announces Study Design for First Clinical Study with the Oligomer-Specific Therapeutic Vaccine ALZ-101 at a Scientific Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Alzinova"},{"company":"Alzinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzinova Presents Preclinical Data on Alzheimer Disease Candidates at the AAIC Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Alzinova"}]

Alzinova

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Alzinova Presents Preclinical Data on Alzheimer Disease Candidates at the AAIC Conference

Details:

The monoclonal antibody, ALZ-201, which specifically targets amyloid Aβ42 oligomers, neutralises the neurotoxicity effect although it only targets a very small fraction of all amyloid Aβ.

Lead Product(s): ALZ-201

Therapeutic Area: Neurology Product Name: ALZ-201

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 26, 2021

ASK
US

Upload
your Pipeline Activity

Alzinova

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Alzinova AB Announces Study Design for First Clinical Study with the Oligomer-Specific Therapeutic Vaccine ALZ-101 at a Scientific Congress

Details:

The study design is today presented on a poster titled: First in Human study with ALZ-101, a unique and highly specific therapeutic vaccine against the neurotoxic oligomeric form of Aβ 1-42.

Lead Product(s): ALZ-101

Therapeutic Area: Neurology Product Name: ALZ-101

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 04, 2020

ASK
US

Upload
your Pipeline Activity

CombiGene

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Cobra Biologics Completes Production of Master Cell Banks for CombiGene’s Epilepsy Gene Therapy Drug Candidate

Details:

Cobra has successfully produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01.

Lead Product(s): CG01

Therapeutic Area: Neurology Product Name: CG01

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Cobra Biologics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 18, 2020

ASK
US

Upload
your Pipeline Activity

AlzeCure Pharma AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AlzeCure Pharma Today Presented Key Preclinical Data on its Novel Cognitive Enhancer at the AAT-AD/PD Conference

Details:

ACD856 significantly increases the levels of key neurotransmitters in the hippocampus - an area known to play a critical role in memory processing .

Lead Product(s): ACD856

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 02, 2020

ASK
US

Upload
your Pipeline Activity

AlzeCure Pharma AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AlzeCure Pharma to Present Late Breaking Abstract at the AAT-AD/PD Conference (Advances in Alzheimer's and Parkinson's Therapies)

Details:

The study demonstrated that the clinical candidate, ACD856, in NeuroRestore platform can effectively prevent the memory impairment associated with normal aging in animals.

Lead Product(s): ACD856

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 16, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY